Eris Lifesciences (NSE:ERIS) Net Income From Continuing Operations : ₹3,789 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Eris Lifesciences Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Eris Lifesciences's net income from continuing operations for the three months ended in Dec. 2023 was ₹1,015 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was ₹3,789 Mil.

Eris Lifesciences Net Income From Continuing Operations Historical Data

The historical data trend for Eris Lifesciences's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eris Lifesciences Net Income From Continuing Operations Chart

Eris Lifesciences Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Income From Continuing Operations

Get a 7-Day Free Trial

3,173.58

3,313.50

3,944.97

4,421.98

4,046.43

Eris Lifesciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial															1,002.31	614.78	936.49	1,223.12	1,014.60

Eris Lifesciences Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,789 Mil.

Eris Lifesciences (NSE:ERIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eris Lifesciences Ltd (NSE:ERIS) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

540596:India

Address

Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054

Website

https://www.eris.co.in

Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.

Eris Lifesciences (NSE:ERIS) Headlines

No Headlines